Pharmaceutical coverage has become an especially important issue in health plan design. This article develops an objective measure of drug coverage generosity in managed care drug formularies. Formulary generosity is important because patients respond differently to drugs within a therapeutic class, and so there is benefit in offering a wide variety of products to prescribing physicians. The measure of coverage generosity considers not only the number of products offered to patients through a formulary, but whether plans systematically exclude more expensive products. The correlation between formulary generosity and health plan member satisfaction is analyzed to see if formulary generosity is perceived by subscribes to be related to perceived health plan quality. The findings are that plans vary widely in offering access to pharmaceuticals but that generosity is not highly correlated with health plan satisfaction.
information on health plan attributes. This article investigates variation in an increasingly important component of health plans, drug coverage, and whether drug formulary generosity is associated with measures of health plan satisfaction-both overall and with respect to access.
Formularies are lists of pharmaceuticals that are approved for reimbursement by a health plan. They encourage use of less costly drugs whenever this is determined to be appropriate by the plan's Pharmacy and Therapeutics (P&T) committee, though these efforts are frequently opposed by physicians and patients who feel that the formulary drug may be inferior to other drugs on the market. Formularies have become a frequently used cost-containment measure by managed care plans.
There have been attempts to rate health plans according to report cards to assist consumers (or their employers) in making informed choices regarding health plans. One attempt is the Healthplan Employer Data and Information Set (HEDIS) developed by the National Committee for Quality Assurance (NCQA). Another is information developed by Medicare to assist the elderly in choosing a Medicare Health Maintenance Organization (HMO). In both of these cases, dimensions thought useful to consumers are perceived satisfaction with plan performance or objective measures of process, often in the area of prevention, such as rates of pediatric immunization and mammograms. They rarely address access to new technology, though this is the issue that has emerged as being especially important for consumers (see Sangl and Wolf 1996; Lohr 1997) . HMO report cards do not assess objective measures of coverage generosity. This article explores differences between HMOs in access to one type of new technology: coverage of pharmaceuticals. It explores whether managed care plans have begun to differentiate themselves according to access to expensive drugs, with some plans offering access only to less expensive therapies (typically older drugs), while other health plans offer more costly, frequently better (and often newer) products. If this is occurring with health plans, information on HMO drug formularies might be useful for people deciding on health plan membership, either individual employees or employers who make a selection decision on behalf of employees. This is especially true of formulary generosity that is correlated with perceived health plan quality.
NEW CONTRIBUTION
The study makes two contributions to the literature on managed care and consumer satisfaction. The first is that it provides an objective assessment of a health plan's generosity with respect to pharmaceutical coverage. The study shows that plans differ widely in their coverage for drugs and that some plans systematically exclude newer, more expensive drugs from their drug formularies. The second is that there is only a weak association between health plan formulary generosity and subjective assessments of enrollee satisfaction, suggesting that formulary generosity (at least for the two drug classes studied) is not a determinant of consumer satisfaction with their plan.
BACKGROUND
Though consumers overwhelmingly choose managed care alternatives when offered the chance, they undoubtedly do so because of substantially lower premiums. Once enrolled, they often express disappointment (Miller and Luft 1997; Tudor, Riley, and Ingher 1998; Hellinger 1998) . According to the Center for Studying Health System Change (1997), 21 percent of insured Americans report that their access to care has decreased during the past 3 years. The most frequent complaint is lack of coverage for services: either specialty care is difficult to obtain, specific treatments are not authorized, or the latest pharmaceutical therapies are unavailable. More than half of the members of restrictive managed care plans felt that their health plans would not cover most of the cost if they had "a serious problem requiring costly treatment" (Blendon et al. 1998, p. 87) .
A health plan's restrictiveness may be driven by the desire to contain costs, especially if excluded services are those with the least favorable cost-effectiveness (C-E) ratio. But the evidence is not strong that this is generally happening. Power and Eisenberg (1998) found that the use of C-E by health plans is still rudimentary at best. The literature on C-E of drugs is extensive, however, and it is possible that C-E is an important criterion for drug coverage decisions. But one need not assume that all managed care plans would make the same coverage decisions concerning a particular C-E ratio used to include or exclude service coverage.
Though perfectly competitive markets are characterized by product homogeneity, imperfectly competitive markets exhibit product differentiation as producers compete for market share (see Chamberlin 1948) . Managed care markets are imperfectly competitive because of the small number of producers in each market area, and so one should expect to see health plans attempting to differentiate themselves according to quality or other attributes.
With appropriate information on quality and cost, consumers can choose health plans according to their personal preferences, but without such information the market is likely to degenerate because only one dimensioncost-is readily measurable. Quality is not. Miller (1996) notes that although there is much competition among managed care plans on the basis of price, "in general, there was almost no competition on the basis of measured and reported technical quality process or outcome measures" (p. 116). Rice (1998) suggests an even more serious problem, that patients fail to use quality information even when it is available. According to Rice, "Consumers typically ignore the data elements that they do not understand-which tend to be the 'objective' measures of quality such as various utilization rates" (p. 2). If consumers either do not have information on health plan quality (or ignore it), one would expect that managed care plans would compete on price alone and would let quality deteriorate, as long as it was maintained at a sufficient level to avoid being identified as dangerous.
Information on pharmaceutical access has not yet been used as a measure of health plan quality, either in its own right or as a correlate of other measures of health plan quality, most notably consumer satisfaction.
A study of variation in benefit generosity among Medicare HMOs, measured by cost-sharing requirements, was recently done by the Barents Group for the Henry J. Kaiser Family Foundation (Langwell, Topoleski, and Sherman 1999) . The study found considerable variation in generosity for prescription drug coverage. Though 80 percent of Medicare HMO enrollees are in plans that offer prescription drugs, the average annual expenditure limit is $1,149. While nearly 25 percent have no limit at all, 11 percent of the enrollees have a limit below $600 per year. Copayment requirements also vary widely, with many plans charging a higher amount for brand name products than for generics. The issue of access, especially to expensive drugs, was not addressed. Though the authors point out the wide variation in prescription drug coverage across health plans, the study only applies to Medicare HMOs and defines generosity more along financial parameters than by access to expensive products.
METHODOLOGY
There are two dimensions of the coverage decision that affect patients. The first is the number of products within a therapeutic category that are available to patients. Drugs differ from one another in terms of efficacy, side-effect profile, and convenience. 1 Drugs in the same therapeutic class often tend to act differently for different patients. Thus, it is advantageous to have numerous drugs within a particular therapeutic class available for patients. Failure to offer a wide variety of drugs restricts physicians to use products that may work well in general but may not be optimal for particular patients. The more open a formulary, the more trust the health plan places with prescribing physicians to choose the best drug for patients, without prescribing more expensive therapies when they are not needed. Health plans typically allow coverage for drugs that are "off formulary," but physicians must comply with significant bureaucratic regulations to obtain an exemption, and the regulations are intended to minimize the number of exemptions that are sought.
The second dimension of a plan's drug coverage decision is coverage for expensive products within a therapeutic class, because these drugs are often the newer products that tend to offer improvement over older drugs but at a higher price. In fact, a recent study shows a positive correlation between a drug's effectiveness and its price, suggesting that drugs can compete in the marketplace at a higher price than existing products if they offer significant therapeutic benefit (Lu and Comanor 1998) .
This study develops a measure of health plan generosity that captures both the number of products included in a formulary and their costliness. It defines coverage of drug i by health plan j as c ij , where c ij = 1 if the drug is covered and 0 otherwise. A health plan's generosity, G j , is the sum over all drugs of the availability of drug i, c ij , weighted by its price, p i , divided by the weighted product if all drugs were available (c ij = 1 for all i). This can be written as
Generosity (G) ranges from 0 to 1. But this formulation of generosity allows a health plan to compensate for the exclusion of a new and expensive drug by covering many older inexpensive products. To avoid this problem, this study allows the weight of the price variable to increase by raising it to a power, β (β ≥ 0). The generalized formula is the following:
If β = 0, G collapses to the fraction of the drugs within a therapeutic class that is covered in a health plan, regardless of price. If β = 1, availability and price are equally weighted. As β rises (β > 1), the weighting of price (relative to that of coverage) i increases. This analysis will consider five values for β: β = 0, β = 1/2, β = 1, β = 2, and β = 3. This article will investigate whether raising β increases the ability to discriminate between various health plans.
This study next tests the hypothesis that health plan members perceive drug formulary generosity as an attribute of health plan quality. A measure of health plan quality that is frequently used by organizations that rate health plans, such as NCQA and Medicare, is enrollee satisfaction as assessed through member surveys. It is the most easily interpreted measure of quality and the measure to which consumers can most directly relate. It is also assumed to best capture future enrollment decisions. Formulary generosity is related to two different measures of consumer satisfaction. The first is overall satisfaction with the plan. This linkage is appropriate to investigate the hypothesis that formulary generosity is a proxy for other favorable health plan characteristics that determine perceived satisfaction. Formulary generosity is, however, a specific measure of health plan coverage. As noted above, coverage issues are a pressing concern of plan members and the source of most formal grievances. To test the hypothesis that formulary generosity is correlated with other health plan access policies, a second analysis tests the association between formulary generosity and member satisfaction with the plan's access to specialists and procedures, a more narrowly defined measure of perceived health plan quality.
Two therapeutic categories were chosen for analysis on the basis of their overall importance in clinical practice: calcium channel blockers (CCBs) and antidepressants (ADs). CCBs are an important group of cardiac drugs used to treat hypertension or irregular heart rhythms (arrhythmia). ADs are the most widely used group of central nervous system drugs and are useful in treating clinical depression.
DATA
The drugs within each class were identified either in the Medical Letter or the Triple i Managed Care Formulary Guide (1997) . 2 The price for each product was obtained from the Medical Letter and Drug Topics Red Book (1996, 1997) , both of which report the Average Wholesale Price (AWP) for each product for a 30-day supply using the lowest frequently prescribed dose for the respective product. The AWP is not necessarily the actual acquisition cost of drugs, especially for managed care plans, because they frequently obtain price discounts from manufacturers. These discounts are proprietary information and were not available for this analysis. Nonetheless, AWP prices are a commonly used proxy for prices that drug purchasers pay, and even though discounted prices would be lower than AWP, relative prices-and especially price rankings-may be well represented by the AWP.
The formulary status of drugs is obtained from a compilation of formularies of major prominent health plans in California published in the Triple i Managed Care Formulary Guide (1997) . This book summarizes individual formularies from 18 managed care plans, including MediCal, California's Medicaid program. The formulary guide includes the formulary status of most (but not all) of the drugs that are available. Coverage for Blue Cross of California is not included in the formulary guide and was obtained directly from that plan's formulary (Blue Cross of California 1997), increasing the sample of health plans to 19. Table 1 presents the drugs for which formulary status and AWP (1996 and 1997) were determined for the 19 health plans. The drugs are grouped according to therapeutic category (CCBs and ADs). AWP refers to the generic version of a product if it is multisource.
The 19 health plans for which formulary data were available are listed in Table 2 . In the remainder of the article, the plans are not identified because the analysis is too preliminary to justify either praise or criticism of specific health plans.
Except for California's Medicaid program, all the plans are Independent Practice Association (IPA)-model HMOs, with the plans contracting with community physicians and hospitals to provide member services. Physicians who agree to treat members of one IPA health plan may also agree to treat members of other plans. Similar nonexclusive contracting applies to hospitals. Group-or staff-model HMOs, in which physicians contract exclusively with an HMO, are not included in the sample. The IPA component of the managed care industry is the fastest growing segment, both nationally and in California.
The association between formulary generosity and health consumer satisfaction is assessed by comparing formulary coverage to broader measures of health plan satisfaction. The database for health plan quality that covers most of the health plans in this data set is produced by the Pacific Business Group on Health (PBGH 1999), a San Francisco-based association composed of representatives of many of the largest employers in California. The quality assessment covers the all non-Medicare enrollees. This HMO quality data set includes health plan quality for 12 of the 18 HMOs. Two dimensions of the PBGH quality assessment instrument are used for this analysis. The first is perceived overall quality of care and the second is perceived satisfaction with access to specialty services. Overall plan satisfaction is perhaps the measure most likely to be used by potential HMO enrollees, but the latter may be more highly correlated with formulary generosity because of the possible similarity in concept between access to expensive pharmaceuticals and access to expensive specialist referrals and procedures.
RESULTS

VARIATION IN PLAN COVERAGE
Though most drugs are covered by the 19 health plans, considerable variation in health plan coverage is evident, as shown in Table 3 (the health plans are not displayed in alphabetical order). For CCBs, for example, coverage of the 15 drugs included in the study ranges from 3/15 (20 percent) to 15/15 (100 percent; = 72.7 percent, SD = 2.94). For ADs, the range in coverage is similar, ranging from 3/16 (19 percent) to 16/16 (100 percent), but the mean is higher and the distribution has lower variance ( = 78.3 percent, SD = 2.82). When coverage is weighted by price, differences in health plan coverage generosity of expensive drugs becomes more apparent. Health plan generosity (G) varies widely, as seen in Table 4 . All five weighting schemes are shown (β = 0 to 3). Note that if β = 0, G merely measures the proportion of drugs covered. As β rises, the weight attached to price increases.
The mean coverage for CCBs is 73 percent (SD = 0.20) and for ADs is 79 percent (SD = 0.17). But the plans vary widely, with a few of them covering less than half of the products within a drug class and some plans covering all drugs with a class.
The definition of G permits an examination that goes beyond counting available drugs to identify plans that systematically exclude the more expensive products. As β rises from 0 to 3 the relative weighting of price increases. If G rises with β, the plan is including higher priced products, while a falling G identifies systematic exclusion of the higher priced products.
For CCBs, for example, most of the Gs rise as β rises from 0 to 3, suggesting that the more expensive CCB drugs are included in the formularies (though the overall generosity, as indicated by G β = 0 ranges from 20 percent to 100 percent). Only two plans (15 and 17) appear to exclude the more expensive products. For ADs, the evidence is reversed. Only Plan 1 (whose overall generosity is the lowest, at 19 percent of drugs covered) has a rising G as β rises from 0 to 3. All the other plans do exclude the more expensive products. The exclusion is especially pronounced for Plans 13 and 18, whose G falls 23 percent and 45 percent, respectively.
Though the study includes only two drug classes-far from the universe of products-an indication of consistency in generosity across drugs within the plans is important. This is measured by the coefficient of correlation between the two series of generosity values. The correlation between G(CCB) and G(AD) for β = 2 is r = 0.36, suggesting that consistency in coverage is not very great. Though the coefficient of correlation is not high, some health plans stand out from the others in terms of their coverage generosity.
HEALTH PLAN GENEROSITY
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• most frugal is G j < (G M -SD) for two drug classes, and • medium is all other plans.
By this definition, there are no most generous health plans, but Plans 4, 7, 10, and 11 are classified as generous. On the other hand, Plans 1 and 15 are most frugal, while Plans 14 and 18 are frugal. The remaining 12 plans are medium. 
FORMULA GENEROSITY AND HEALTH PLAN SATISFACTION
Correlation (ρ) between G j (β = 2) and overall plan satisfaction was 0.52 for CCB drugs, 0.01 for AD, and 0.28 for the mean of G j (CCB) and G j (AD). While the signs of ρ were all positive, none of the p values was less than .10, indicating lack of statistical significance for the correlation coefficients.
The hypothesis that the correlation between drug coverage generosity would be higher for satisfaction with access to referrals and specialty services was not confirmed. The correlation coefficient (ρ) between G j (CCB) and G j (AD), and G j (mean) and satisfaction with referrals, was 0.45, 0.09, and 0.27. Again, all of the signs of ρ were positive, but none of their p values was as low as .10, suggesting that the correlation coefficients are not significantly greater than zero. The generally low correlation between each of the satisfaction measures and each of the G j is notable, but the associations between both satisfaction measures and the G j (CCB) were much higher than with G j (AD). This suggests perhaps that more beneficiaries are taking CCBs than ADs, and hence more beneficiaries are aware of G j (CCB) than G j (AD), or that there is greater clinical difference between drugs within the CCB class than within the AD class, so that beneficiaries feel more keenly differences in coverage between drugs in the CCB class than in the AD class. Or perhaps G j (CCB) and perceived quality are both better correlated with unmeasured plan traits than are G j (AD) and perceived quality. It is of course impossible to infer causality from univariate regression analyses.
CONCLUSIONS
These findings indicate that coverage of pharmaceuticals by the managed care plans studied tended to be broad, with most health plans covering most drugs in each drug class. There was, however, wide variation in health plan coverage for pharmaceuticals, with some plans standing out as being either especially generous or especially frugal. The fact that wide variation exists across health plans suggests that consumers who are concerned about access to drugs (and especially expensive products) may benefit from wider dissemination of drug coverage information.
Formulary generosity does not appear to be correlated with measures of perceived health plan satisfaction, for the correlations between coverage generosity and either overall health plan satisfaction or satisfaction with a plan's access to specialty care are not statistically significant.
It is possible that health plan members are ill informed about drug coverage generosity and therefore do not take it into consideration when they rate the plan. It is also possible that drug coverage generosity is only weakly correlated with other dimensions of coverage generosity that members value more. And, of course, it is possible that this measure of generosity, based on only two drug classes, does not capture actual generosity, which consumers may both perceive and value. A more comprehensive study including a larger number of therapeutic drug classes would determine whether coverage generosity tends to be consistent across drug class for a health plan. In this preliminary inquiry, only two classes are included in the analysis, and though the association between each plan's generosity for the respective class is weak, one cannot infer that the association is weak across all important therapeutic groups.
A more comprehensive study would be necessary to better understand the nature of health plan formulary generosity and to make inferences about the actual relationship between formulary generosity and enrollee satisfaction.
NOTES
1. Convenience has numerous dimensions, including frequency of administration (the fewer times per day, the more convenient), route of administration (pills or tablets are more convenient than liquid dosing or an injection), and temperature sensitivity (drugs that are stable at room temperature are more convenient than those that require refrigeration. 2. The Medical Letter is published by The Medical Letter, Inc., located in New Rochelle, New York. Data were obtained from selected issues. 3. The definition of generous in which G j > (G M + SD) for one drug class is only one of many definitions, of course. For example, generous could be defined more restrictively as G j > (G M + SD) for one class and not G j > (G M -SD) for the other. By this definition, the same plans would be rated as generous and frugal. If the data included more than two drug classes, a measure of generosity might need to reflect the number of classes n G rated as generous by a plan; n G might stand alone or might also consider the number of frugal classes, n F , especially if one noted that some plans were both generous and frugal for different drug classes.
